Targeting NMNAT1 to Axons and Synapses Transforms Its Neuroprotective Potency<i>In Vivo</i>
Elisabetta Babetto(The Ohio State University Wexner Medical Center), Michael P. Coleman(Babraham Institute)
Cited by 123
Related Papers
SCG10 is a JNK target in the axonal degeneration pathway
|Proceedings of the National Academy of Sciences|2012|200
Alzheimer’s Disease: Etiology, Neuropathology and Pathogenesis
|Exon Publications eBooks|2020|93
NMNAT2 is a druggable target to drive neuronal NAD production
|Nature Communications|2024|36
Mitochondrial impairment activates the Wallerian pathway through depletion of NMNAT2 leading to SARM1-dependent axon degeneration
|bioRxiv (Cold Spring Harbor Laboratory)|2019|10